NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Sanofi Consumer Healthcare Seeks Approval for Rs 530.1 Cr Material Related Party Transactions
Sanofi Consumer Healthcare India Limited has dispatched a Postal Ballot notice seeking shareholder approval for material related party transactions (RPTs) for CY 2027. The proposed transactions include up to Rs 150.1 crore (Rs 1,501 million) with Opella Healthcare India Private Limited and up to Rs 380 crore (Rs 3,800 million) with Opella SAS. The Rs 380 crore transaction alone represents 43.26% of the company's annual turnover, primarily covering the import of finished goods, central API sourcing, and exports. The e-voting window runs from 7th November 2026 to 6th December 2026, with voting results expected on or before 8th December 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company initiated a postal ballot for shareholder sanction of large RPT contracts scheduled for calendar year 2027.
ஏன் இது முக்கியம்These transactions are vital for core operations, representing over 43% of turnover, ensuring continuous exclusive supply of finished formulations and central API procurement from the parent Opella group.
RPT cap with Opella India: Rs. 1501 MillionRPT cap with Opella SAS: Rs. 3800 MillionOpella SAS RPT as % of turnover: 43.26%E-voting end date: 6th டிசம்பர் 2026
📅 குறுகிய காலம்Neutral operational update; normal voting process expected without market price disruption.
📈 நீண்ட காலம்Secures essential supply chain linkages and product import frameworks from the Opella group for CY 2027.
⚠ அபாய எச்சரிக்கைகள்
High dependence on parent entity Opella SAS for critical finished goods and API procurement without external bidding
👀 கவனிக்க வேண்டியவை
Track the outcome of the postal ballot voting on 8th December 2026 to ensure ordinary resolutions for supply-chain related party contracts are ratified smoothly.
Sanofi India Declares Rs 75/Share Interim Dividend; Details TDS Procedures
Sanofi India Limited has announced an interim dividend of Rs 75 per equity share of face value Rs 10 for the financial year 2026. The record date to determine eligible shareholders is set for November 5, 2026. Relative to the current share price of Rs 3,189.5, this dividend translates to a yield of approximately 2.35%. The company has also outlined Tax Deduction at Source (TDS) guidelines requiring relevant tax documentation to be submitted by 5:00 PM IST on November 5, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுSanofi India announced an interim dividend payout of Rs 75 per share and initiated the shareholder tax withholding communication process.
ஏன் இது முக்கியம்The payout represents a substantial cash return to shareholders (around 2.35% yield) funded from operational earnings, reflecting continuing dividend distribution policies.
Interim Dividend per share: Rs 75முக மதிப்பு: Rs 10ரெக்கார்ட் தேதி: 5th நவம்பர் 2026TDS Submission Deadline: 5th November 2026, 5.00 p.m. ISTடிவிடெண்ட் ஈல்ட்: ~2.35%
📅 குறுகிய காலம்The stock will trade cum-dividend until shortly before the November 5, 2026 record date, after which it will adjust for the Rs 75 per share payout.
📈 நீண்ட காலம்Limited; reflects regular ongoing capital allocation and dividend distribution practices.
👀 கவனிக்க வேண்டியவை
Shareholders seeking lower withholding tax rates must submit valid tax exemption certificates or DTAA declarations via the RTA portal before November 5, 2026.
Sanofi Consumer Q3 PAT Rises 22% YoY to ₹76.6 Cr; Revenue Up 12% to ₹263.1 Cr
Sanofi Consumer Healthcare India reported a 12.5% YoY rise in revenue from operations to ₹263.1 crore (₹2,631 million) for the quarter ended September 30, 2026, compared to ₹233.9 crore in Q3 2025. Profit after tax grew 21.8% YoY to ₹76.6 crore (₹766 million) from ₹62.9 crore, driven by 19% domestic sales growth following the full relaunch of previously recalled products. Operating PBT climbed 22.1% YoY to ₹102.7 crore, with quarterly basic EPS expanding to ₹33.26 from ₹27.31. For the nine-month period, revenue rose 16% to ₹728.0 crore while PAT grew 22.8% to ₹213.2 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுSanofi Consumer Healthcare India declared its Q3 2026 financial results showing double-digit growth in top-line and bottom-line.
ஏன் இது முக்கியம்Demonstrates successful market share recovery and commercial traction across core OTC brands post the complete resolution of the 2024–2025 product recalls.
📅 குறுகிய காலம்The strong 22% earnings growth and sustained 19% domestic growth should support sentiment, particularly after the stock's ~30% correction over recent months.
📈 நீண்ட காலம்The business exhibits solid cash-generative characteristics with strong brand moats (Allegra, Combiflam, Avil), though long-term growth hinges on OTC market formalisation and parent Opella strategy.
⚠ அபாய எச்சரிக்கைகள்
Prior history of voluntary product recalls impacting sales continuity
Regulatory sensitivity surrounding OTC medicine classifications in India
👀 கவனிக்க வேண்டியவை
Track sustaining volume growth and operating margins in Q4 2026 now that the low base effect from recalled suspensions (Combiflam, Allegra, Depura Kids) has largely played out.
Supreme Court Dismisses Sanofi India's Plea to Quash CBI Criminal Proceedings in BARC Case
The Supreme Court of India on September 7, 2026, dismissed Sanofi India Limited's petition seeking to quash criminal proceedings initiated by the Central Bureau of Investigation (CBI). The matter pertains to pharmaceutical supplies made to Bhabha Atomic Research Centre (BARC), Mysore between 2012 and 2015, alleging conspiracy to influence procurement decisions. The Supreme Court ruled that criminal prosecution against the company is maintainable even if no individual employee is arraigned, without ruling on the merits or finding guilt. The criminal complaint remains pending for trial, and no monetary penalty or operational restriction has been imposed at this stage.
உச்சம் நம்பிக்கை
என்ன மாறியதுSanofi India's appeal to quash a CBI criminal complaint was dismissed by the Supreme Court, allowing the trial to proceed against the corporate entity.
ஏன் இது முக்கியம்While there is no immediate financial penalty, the company now faces an active criminal trial related to historical 2012–2015 procurement practices, introducing legal and reputational uncertainty.
Date of Supreme Court Order: 7th செப்டம்பர் 2026Period of alleged BARC supplies: 2012 to 2015Financial penalty imposed: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Neutral to cautious sentiment; markets may react slightly to the continuation of CBI proceedings, though no immediate cash outflow or operational ban exists.
📈 நீண்ட காலம்Outcome will depend on the final trial verdict; potential risks include reputational impact and any eventual fines or restrictions on government tendering if convicted.
⚠ அபாய எச்சரிக்கைகள்
Pending criminal trial initiated by the Central Bureau of Investigation (CBI)
Reputational and potential regulatory risks regarding government procurement
👀 கவனிக்க வேண்டியவை
Track subsequent legal disclosures regarding trial proceedings in the CBI court or any review petitions filed by the company.
Sanofi Receives ₹72.77 Cr GST Show Cause Notice for FY21 Product Classification
Sanofi India Limited received a Show Cause Notice dated August 28, 2026, from the Additional Commissioner of CGST and CX, Mumbai East. The notice alleges misclassification of certain products at a 5% GST rate instead of 12% during FY 2020-21. The authority has proposed a tax demand of ₹36.39 Cr along with an equal penalty of ₹36.39 Cr, totaling ₹72.77 Cr. The total proposed demand represents approximately 39.2% of Sanofi's TTM net profit (₹185 Cr), though the company intends to contest the notice within prescribed timelines.
உச்சம் நம்பிக்கை
என்ன மாறியதுGST authorities issued a show-cause notice proposing ₹72.77 Cr in combined tax and penalties for FY21 product classification.
ஏன் இது முக்கியம்The ₹72.77 Cr exposure equals ~39.2% of TTM net profit (₹185 Cr), making it a notable contingent tax risk if upheld during adjudication.
📅 குறுகிய காலம்Minimal immediate cash impact as this is a show-cause notice stage; Sanofi will submit a legal reply.
📈 நீண்ட காலம்If the demand crystallizes into an adverse order, it may lead to prolonged appellate litigation or one-time exceptional provisioning.
⚠ அபாய எச்சரிக்கைகள்
Adverse tax adjudication upholding the 12% GST rate
Potential penalty and interest liabilities if appeals are dismissed
👀 கவனிக்க வேண்டியவை
Monitor the company's formal submission of reply to tax authorities and any subsequent adjudication orders or provisioning requirements in upcoming quarterly results.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
14% Diabetes Growth and 70% Public Sector Expansion Highlight Q2 2026 Performance
Sanofi India reported a 7% growth in total income for Q2 2026, driven by a 14% increase in its core diabetes business. The company maintains a dominant 58% value share in the basal analog market, with its innovative product Soliqua growing 16% sequentially. While YTD sales remain down 4% due to Q1 transition issues, management highlighted a significant 70% growth in public sector accounts. The company is also restructuring its export strategy to offset losses in the Australian market by targeting France, Italy, and Russia.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully stabilized its diabetes franchise following a 2025 transformation, shifting focus toward public sector expansion and innovative products like Soliqua and Toujeo.
ஏன் இது முக்கியம்Diabetes is the company's primary growth engine; maintaining a 58% market share in basal analogs provides a strong defensive moat and high-margin revenue stream to offset export volatility.
Diabetes segment growth (Q2): 14%Public sector growth: 70%Basal analog value share: 58%Soliqua QoQ growth: 16%Total income growth (Q2): 7%YTD Sales growth: -4%
📅 குறுகிய காலம்The recovery in the diabetes segment and strong public sector growth are likely to be viewed positively by the market in the coming weeks as they signal a turnaround from a weak Q1.
📈 நீண்ட காலம்The structural shift toward innovative diabetes therapies and AI-driven supply chain forecasting (targeting +/- 1% accuracy) supports long-term margin stability, though export market transitions remain a key variable.
⚠ அபாய எச்சரிக்கைகள்
Export revenue losses in mature markets like Australia
Potential impact of GLP-1 biosimilars on insulin initiation
Regulatory pricing risks in the diabetes segment
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the 14% diabetes growth and the execution of the export pivot to Europe and Russia. Watch for further updates on the potential open market buyback, which management confirmed has been discussed at the board level but is not currently in the active strategy.
19% PBT Growth in Q2; Diabetes Segment Grows 17% in H1 2026
Sanofi India reported a strong Q2 2026 with Profit Before Tax (PBT) rising 19% YoY to ₹112.3 crore, despite a modest 6% growth in domestic sales to ₹416.2 crore. The performance was driven by a 17% growth in the Diabetes business unit during H1 2026 and a 5% reduction in operating expenses. The company maintained a dominant 58% value market share in the basal analog insulin segment and saw a 70% acceleration in public sector accounts for key products Toujeo and Soliqua. However, export sales faced headwinds, declining 7% YoY in H1 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுSanofi has completed its strategic transformation, shifting focus toward its core Insulin portfolio and a partnership model for legacy brands, resulting in significant margin expansion.
ஏன் இது முக்கியம்The 19% PBT growth on 6% revenue growth demonstrates high operational leverage and successful cost optimization, positioning the company to capture India's high-growth diabetes market more profitably.
📅 குறுகிய காலம்The stock may react positively to the margin expansion and strong double-digit growth in the core diabetes segment despite export weakness.
📈 நீண்ட காலம்The structural shift to a leaner, insulin-focused model and AI-driven supply chain improvements (targeting +/- 1% forecasting accuracy) supports long-term profitability.
⚠ அபாய எச்சரிக்கைகள்
Export business headwinds (-7% growth)
Regulatory pricing risks in the insulin segment
Concentration risk in the diabetes therapeutic area
👀 கவனிக்க வேண்டியவை
Monitor the sustainability of the 17% diabetes segment growth and the impact of the Emcure partnership on legacy brand margins. Watch for a potential recovery in the export business, which currently shows a 7% decline.
Sanofi Consumer Q2 Net Profit Up 13% to ₹68.8 Cr; Domestic Sales Grow 12%
Sanofi Consumer Healthcare India (SCHIL) reported a 7% YoY revenue growth to ₹235.7 cr for Q2 2026, driven by a strong 12% increase in domestic sales following product relaunches. Net profit for the quarter rose 13.3% to ₹68.8 cr, while Profit Before Tax (PBT) grew 16% YoY to ₹91.9 cr. The first half of 2026 (H1) shows stronger momentum with revenue up 18% and PBT up 25% YoY. The company maintains a robust liquidity position with cash and bank balances of ₹490.2 cr as of June 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully transitioned into a standalone entity post-demerger, showing consistent double-digit domestic growth and brand recovery.
ஏன் இது முக்கியம்The results validate the 'India for India' strategy and the resilience of core brands like Allegra and Combiflam after historical product recall challenges.
Q2 வருவாய்: ₹2,357 millionQ2 Net Profit: ₹688 millionDomestic Sales Growth (Q2): 12%PBT Margin (Q2): 39%Cash and Bank Balances: ₹4,902 million
📅 குறுகிய காலம்The stock may see positive sentiment as PBT growth (16%) outpaced revenue growth (7%), indicating healthy margin management.
📈 நீண்ட காலம்The structural shift to a specialized consumer healthcare entity allows for better focus on OTC categories; H1 growth of 18% suggests a strong trajectory.
⚠ அபாய எச்சரிக்கைகள்
Export volatility (-9% in Q2)
Regulatory risks regarding OTC drug classifications
Concentration in consumer healthcare segment
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the 12% domestic growth as the 'relaunch' impact normalizes and track the recovery of export sales, which declined 9% this quarter due to a high base.
CFO Rachid Ayari to Step Down Effective September 30, 2026
Mr. Rachid Ayari has resigned as the Whole Time Director and Chief Financial Officer of Sanofi India, effective September 30, 2026. The resignation is due to his transition to another role within the global Sanofi group, suggesting an orderly internal movement rather than an external departure. The company has initiated the process to identify a successor for the CFO and Key Managerial Personnel roles. Given the announcement was made in July 2026 for a September 2026 exit, there is a sufficient transition window for the incoming leadership.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Chief Financial Officer and Whole Time Director is transitioning out of the Indian entity to a new role within the global Sanofi organization.
ஏன் இது முக்கியம்While CFO changes are significant for financial oversight, the internal nature of this move and the long lead time reduce risks associated with financial reporting or strategic shifts.
Effective Date of Cessation: செப்டம்பர் 30, 2026TTM வருவாய்: Rs 988 கோடிTTM PAT: Rs 185 கோடிசந்தை மதிப்பு: Rs 7792 கோடி
📅 குறுகிய காலம்The stock is unlikely to see significant volatility from this news as the exit is planned well in advance and is an internal group movement.
📈 நீண்ட காலம்Limited structural impact expected, provided the successor maintains the current focus on AI-driven supply chain efficiency and strategic partnerships.
⚠ அபாய எச்சரிக்கைகள்
Management transition risk
👀 கவனிக்க வேண்டியவை
Monitor the announcement of the successor CFO to ensure continuity in the company's 'pivotal transformation' strategy and its expansion into the Rs 450-500 Cr human insulin cartridge market.
Sanofi Consumer Healthcare India Limited (SCHIL) has concluded its 3rd Annual General Meeting, with shareholders approving all proposed resolutions. A significant final dividend of Rs 75 per equity share for the financial year ended December 31, 2025, was ratified. While all resolutions passed, the appointment of Price Waterhouse & Co as Statutory Auditors saw notable institutional dissent at 42.72%, though it passed with an overall 91.27% majority. The company remains focused on its 'India for India' strategy following the global Opella group restructuring.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders have formally ratified the FY2025 financial statements, the Rs 75 per share dividend, and the appointment of new Statutory Auditors.
ஏன் இது முக்கியம்This ensures corporate governance continuity and confirms the cash distribution to shareholders, reflecting the company's ability to maintain high payouts despite a slight margin compression in CY2024.
Final Dividend: Rs 75 per shareTotal Shareholders: 49,698Institutional Dissent (Res 4): 42.72%Overall Voting Majority: 91.27%Promoter Votes: 16,414,217
📅 குறுகிய காலம்The stock may see routine price adjustments around the dividend record and payment dates; no major immediate volatility is expected from these results.
📈 நீண்ட காலம்Limited structural impact as the meeting was routine, but the high dividend payout confirms the business remains a strong cash generator for the parent group.
⚠ அபாய எச்சரிக்கைகள்
Significant institutional dissent (42.72%) on the appointment of statutory auditors
👀 கவனிக்க வேண்டியவை
Investors should monitor the dividend credit timeline and watch for the next quarterly results to verify if the 13% expected growth rate is being met through the 'India for India' strategy.
Sanofi Consumer Healthcare India Approves Rs 75 Dividend at 3rd AGM
Sanofi Consumer Healthcare India Limited (SANOFICONR) successfully conducted its 3rd Annual General Meeting on June 26, 2026. A key outcome was the approval of a substantial final dividend of Rs. 75 per equity share for the financial year ended December 31, 2025. The company also confirmed the appointment of Price Waterhouse & Co as statutory auditors and re-appointed Mr. Stanislas Camart as a Director. Management addressed shareholder queries regarding the company's 2025 financial performance and future strategic initiatives.
முக்கிய அம்சங்கள்
Approval of a final dividend of Rs. 75 per equity share of face value Rs. 10 for FY2025Adoption of audited standalone financial statements for the year ended December 31, 2025Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as Statutory AuditorsRe-appointment of Mr. Stanislas Camart as Director following his retirement by rotationManagement provided a strategic overview of business performance and key developments to shareholders
👀 கவனிக்க வேண்டியவை
Investors should track the record date for the Rs. 75 dividend to ensure eligibility for this high-yield payout. The company's ability to maintain such dividends should be monitored alongside its standalone growth performance.
Sanofi Consumer Healthcare India to Hold 3rd AGM; Proposes ₹75 Final Dividend
Sanofi Consumer Healthcare India Limited (SANOFICONR) has scheduled its 3rd Annual General Meeting for June 26, 2026. The Board has recommended a substantial final dividend of ₹75 per equity share for the financial year ended December 31, 2025. The record date for dividend eligibility is June 19, 2026, with the payment scheduled for July 9, 2026. Other key agenda items include the appointment of Price Waterhouse & Co as Statutory Auditors for a five-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹75 per equity share of ₹10 each for FY 2025.3rd Annual General Meeting (AGM) scheduled for June 26, 2026, via Video Conferencing.Record date for dividend entitlement is June 19, 2026; payout date is July 9, 2026.Proposed appointment of Price Waterhouse & Co Chartered Accountants LLP as Statutory Auditors for 5 years.Ratification of ₹3,15,000 remuneration for Cost Auditors M/s. Kishore Bhatia & Associates for FY 2026.
👀 கவனிக்க வேண்டியவை
Investors should ensure their bank details and tax residency documents are updated with the RTA by June 19, 2026, to receive the ₹75 dividend. The high dividend payout reflects strong cash flow and shareholder focus.
Sanofi Consumer Healthcare Sets June 19, 2026, as Record Date for Final Dividend
Sanofi Consumer Healthcare India Limited has announced the timeline for its final dividend for the financial year 2025. The company has fixed June 19, 2026, as the record date to determine shareholder eligibility for the payout. The 3rd Annual General Meeting (AGM) is scheduled for June 26, 2026, via video conferencing. The register of members will remain closed from June 20 to June 26, 2026, for the purpose of this dividend distribution.
முக்கிய அம்சங்கள்
Record date for FY 2025 final dividend is fixed as June 19, 2026Book closure period scheduled from June 20, 2026, to June 26, 20263rd Annual General Meeting (AGM) to be held on June 26, 2026, at 3:00 p.m. ISTDividend will be paid to beneficial owners as per NSDL and CDSL records as of June 19, 2026
👀 கவனிக்க வேண்டியவை
Investors seeking the final dividend should ensure they hold shares in their demat accounts before the record date of June 19, 2026. Monitor the upcoming Annual Report for the specific dividend amount per share.
Sanofi Consumer Healthcare Appoints PwC as Statutory Auditor for 5-Year Term
Sanofi Consumer Healthcare India Limited has appointed Price Waterhouse & Co Chartered Accountants LLP (PwC) as its new Statutory Auditor. This appointment fills the casual vacancy created by the resignation of M/s. Kalyaniwalla & Mistry LLP on April 30, 2026. The Board has also recommended PwC for a full five-year term from 2026 to 2031, subject to shareholder approval at the upcoming Annual General Meeting. The transition to a Big Four affiliate firm is typically seen as a positive step for enhancing corporate governance and financial reporting credibility.
முக்கிய அம்சங்கள்
Appointment of PwC to fill casual vacancy effective May 25, 2026, until the next AGM.Recommended 5-year term for PwC starting from the 2026 AGM through to the 2031 AGM.The change follows the resignation of previous auditors M/s. Kalyaniwalla & Mistry LLP on April 30, 2026.PwC India network has over 120 Assurance Partners and 17 branch offices as of April 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the appointment of a globally recognized audit firm as a positive governance move. No immediate action is required other than noting the change for future financial reporting cycles.
Sanofi Consumer Healthcare Statutory Auditor Resigns Due to Audit Fee Dispute
M/s. Kalyaniwalla & Mistry LLP has resigned as the statutory auditor of Sanofi Consumer Healthcare India Limited, effective April 30, 2026. The firm cited the commercial unviability of continuing the audit after the company declined a requested fee increase for FY 2026. The auditors were originally appointed for a five-year term ending in 2028. Notably, the outgoing auditors confirmed there are no other material concerns or issues with obtaining audit evidence.
முக்கிய அம்சங்கள்
Statutory Auditor M/s. Kalyaniwalla & Mistry LLP resigned effective April 30, 2026.The resignation follows the company's refusal to accommodate a fee increase requested on April 25, 2026.The auditor was in the second year of a five-year term originally scheduled to run from 2024 to 2028.Auditor confirmed no concerns regarding financial statements or inability to obtain audit evidence.
👀 கவனிக்க வேண்டியவை
Investors should monitor the appointment of a successor auditor to ensure a smooth transition. While auditor resignations can be a red flag, the explicit mention of a fee dispute suggests this is a commercial disagreement rather than a sign of financial irregularity.
Sanofi India Appoints Rahul Bhatnagar as Chairman; Succeeds Aditya Narayan
Sanofi India Limited has appointed Mr. Rahul Bhatnagar as the Chairman of its Board of Directors, effective April 30, 2026. He succeeds Mr. Aditya Narayan, who completed a distinguished 10-year tenure with the company. Mr. Bhatnagar, a Chartered Accountant and Wharton MBA, has been a member of the SIL Board since 2020 and brings extensive leadership experience from Nestlé, PepsiCo, and the Bharti Group. Additionally, the company announced the completion of Independent Director Mrs. Usha Thorat's tenure as of April 29, 2026.
முக்கிய அம்சங்கள்
Mr. Rahul Bhatnagar appointed as Chairman of the Board effective April 30, 2026.Outgoing Chairman Aditya Narayan concludes a decade-long tenure with the company.Mr. Bhatnagar has served on SIL's Board since 2020 across Audit and Risk Management committees.Independent Director Mrs. Usha Thorat's tenure ended on April 29, 2026.The new Chairman brings global experience from leadership roles at Nestlé and PepsiCo.
👀 கவனிக்க வேண்டியவை
This is a planned leadership transition involving an experienced internal board member, suggesting continuity in governance. Investors should maintain their positions as this change is unlikely to disrupt short-term operations.
Sanofi Consumer Healthcare Q1 26: Revenue Up 33% to ₹2,292 MN, PAT Rises 36%
Sanofi Consumer Healthcare India (SCHIL) reported a strong Q1 2026 with total revenue reaching ₹2,292 million, a 33% year-on-year increase. Net profit for the quarter grew by 36% to ₹678 million, reflecting disciplined execution and market share gains. Domestic sales were up 15.5%, significantly aided by the relaunch of recalled products, while export sales surged 144% due to a low base effect. This performance marks a positive trajectory for the company following its demerger from Sanofi India in June 2024.
முக்கிய அம்சங்கள்
Total Revenue grew 33% YoY to ₹2,292 million in Q1 2026Net Profit (PAT) increased by 36% YoY to ₹678 millionDomestic sales grew by 15.5%, supported by product relaunches and market share gainsExport sales saw a significant 144% growth, primarily due to a low base in the previous yearKey brands like Allegra, DePURA, Avil, and Combiflam continue to drive the consumer healthcare portfolio
👀 கவனிக்க வேண்டியவை
The strong double-digit growth in both top-line and bottom-line suggests the demerged entity is scaling well; investors should monitor the sustainability of domestic volume growth. The successful relaunch of recalled products is a key positive catalyst for future quarters.
Sanofi India Shareholders Approve ₹123 Total Dividend and New Board Appointments at 70th AGM
Sanofi India Limited's shareholders have approved all 11 resolutions at the 70th Annual General Meeting held on April 29, 2026. A key highlight is the approval of a ₹48 per share final dividend, which combined with the ₹75 interim dividend, brings the total payout for FY2025 to ₹123 per share. The meeting also confirmed the appointment of Sudipta Chakraborty as Whole-time Director and two new Independent Directors for five-year terms. Furthermore, material related-party transactions with Sanofi-Aventis Singapore were cleared by the members.
முக்கிய அம்சங்கள்
Final dividend of ₹48 per share approved, resulting in a total FY2025 payout of ₹123 per share.Appointment of Sudipta Chakraborty as Whole-time Director passed with 99.92% majority.Two Independent Directors, Rajani Kesari and Siraj Azmat Chaudhry, appointed for 5-year terms until 2031.All resolutions, including the adoption of FY2025 financial statements and related-party transactions, passed with requisite majority.
👀 கவனிக்க வேண்டியவை
Investors should note the high total dividend payout of ₹123 per share for FY2025, which continues Sanofi's trend of strong shareholder returns. The successful board appointments ensure governance stability and leadership continuity.
Sanofi India Appoints Rahul Bhatnagar as Chairman; Q1 Net Profit at ₹1,026 Million
Sanofi India has appointed Mr. Rahul Bhatnagar as the new Chairman of the Board effective April 30, 2026, following the completion of tenure for two independent directors. For the quarter ended March 31, 2026, the company reported a revenue of ₹4,723 million, a decline from ₹5,359 million in the same period last year. Net profit also saw a decrease to ₹1,026 million from ₹1,195 million YoY, primarily due to partnership transitions. However, the core insulin portfolio remains a bright spot, delivering a strong 19% year-on-year growth.
முக்கிய அம்சங்கள்
Mr. Rahul Bhatnagar appointed as Chairman of the Board effective April 30, 2026.Q1 2026 revenue from operations stood at ₹4,723 million, down 11.8% from ₹5,359 million in Q1 2025.Net profit for the quarter decreased to ₹1,026 million compared to ₹1,195 million in the previous year.Insulin portfolio achieved double-digit growth of 19% YoY and 14% sequentially.Tenure of Independent Directors Mr. Aditya Narayan and Mrs. Usha Thorat ends on April 29, 2026.
👀 கவனிக்க வேண்டியவை
Investors should watch for the stabilization of partnership transitions which impacted this quarter's revenue. The continued double-digit growth in the insulin segment suggests strong market positioning in core therapeutic areas.
Sanofi India Q1 PAT at ₹1,026M; Rahul Bhatnagar Appointed Chairman as Insulin Sales Grow 19% YoY
Sanofi India reported a Profit After Tax of ₹1,026 million for the quarter ended March 31, 2026, showing a strong sequential recovery from the previous quarter's ₹617 million. While revenue of ₹4,723 million was lower than the same period last year (₹5,359 million), the company's core insulin portfolio showed significant momentum with 19% year-on-year growth. The board also underwent a leadership transition, appointing Rahul Bhatnagar as the new Chairman effective April 30, 2026. Management noted that while partnership transitions impacted overall quarterly results, export sales are beginning to stabilize.
முக்கிய அம்சங்கள்
Net Profit for Q1 2026 stood at ₹1,026 million, representing a 66% sequential increase from Q4 2025.Revenue from operations reached ₹4,723 million, a decline of 11.8% compared to ₹5,359 million in Q1 2025.The Insulin portfolio delivered exceptional performance with 19% YoY and 14% QoQ growth.Rahul Bhatnagar appointed as Chairman of the Board effective April 30, 2026, following the completion of tenures of two independent directors.Basic and diluted Earnings Per Share (EPS) for the quarter was ₹44.55, down from ₹51.89 in the previous year's quarter.
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of ongoing partnership transitions on revenue and margins, while keeping a close eye on the continued growth of the high-margin insulin segment. The leadership change appears to be a planned transition, but the year-on-year decline in top-line performance requires a cautious outlook.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
